Withdrawal of Registration Statement (rw)
September 27 2016 - 9:17AM
Edgar (US Regulatory)
September 27, 2016
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549-4561
Attention:
|
James Lopez
|
|
|
Re:
|
Opiant Pharmaceuticals, Inc. (the “Registrant”)
|
|
Withdrawal of Registration Statement on Form S-1 (File No. 333-210582)
|
Dear Mr. Lopez:
Pursuant to Rule 477 promulgated under the
Securities Act of 1933, as amended, the Registrant hereby respectfully requests that the U.S. Securities and Exchange Commission
(the “
Commission
”) consent to the withdrawal, effective as of the date hereof or at the earliest practicable
date hereafter, of its Registration Statement on Form S-1 (File No. 333-210582), together with all exhibits thereto (collectively,
the “
Registration Statement
”). The Registration Statement was initially filed with the Commission on
April 4, 2016 and the Registrant filed amendments to the Registration Statement on May 13, 2016, June 10, 2016, August 24, 2016
and September 7, 2016. The Registration Statement has not been declared effective.
The Registration Statement was filed to
register the resale of up to 2,060,715 shares of common stock of the Registrant, par value $0.001 per share (the “
Common
Stock
”), consisting of (i) 15,715 shares of Common Stock, (ii) 45,000 shares of Common Stock to be issued upon the
exercise of Registrant warrants and (iii) 2,000,000 shares of Common Stock to be issued upon the exercise of Registrant options
(collectively, the “
Shares
”).
The Registrant desires to withdraw its Registration
Statement at this time and intends to seek registration of the Shares at a later date.
The Registrant confirms that no securities
were sold pursuant to the Registration Statement.
Thank you for your consideration of
this request. Should you have any questions or require further information regarding this request, please contact David C.
Schwartz, Esq. of DLA Piper LLP (US) by phone at 973-520-2555, by facsimile at 973-520-2575, or by email at
david.schwartz@dlapiper.com.
|
Very truly yours,
|
|
|
|
OPIANT PHARMACEUTICALS, INC.
|
|
|
|
|
|
/s/ Kevin Pollack
|
|
Kevin Pollack
|
|
Chief Financial Officer
|
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Sep 2023 to Sep 2024